Omega Therapeutics (OMGA)

$1.22

-0.14

(-10.29%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $1.22
    $1.39
    $1.22
    downward going graph

    0.0%

    Downside

    Day's Volatility :12.5%

    Upside

    12.5%

    downward going graph
  • $1.22
    $6.30
    $1.22
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :80.63%

    Upside

    80.63%

    downward going graph

Returns

PeriodOmega TherapeuticsSector (Health Care)Index (Russel 2000)
3 Months
-42.45%
5.1%
0.0%
6 Months
-70.32%
5.1%
0.0%
1 Year
-62.58%
16.6%
0.0%
3 Years
-94.02%
13.2%
-21.4%

Highlights

Market Capitalization
67.3M
Book Value
$0.48
Earnings Per Share (EPS)
-1.42
Wall Street Target Price
11.14
Profit Margin
0.0%
Operating Margin TTM
-776.95%
Return On Assets TTM
-25.37%
Return On Equity TTM
-129.15%
Revenue TTM
6.3M
Revenue Per Share TTM
0.11
Quarterly Revenue Growth YOY
181.20000000000002%
Gross Profit TTM
-74.0M
EBITDA
-78.9M
Diluted Eps TTM
-1.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.11
EPS Estimate Next Year
-0.91
EPS Estimate Current Quarter
-0.36
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Omega Therapeutics(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 813.11%

Current $1.22
Target $11.14

Technicals Summary

Sell

Neutral

Buy

Omega Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Omega Therapeutics
Omega Therapeutics
-21.29%
-70.32%
-62.58%
-94.02%
-92.37%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.63%
16.79%
36.21%
69.09%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
2.32%
-1.45%
34.23%
160.46%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-8.76%
64.72%
22.51%
32.46%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.44%
13.16%
36.42%
144.55%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Omega Therapeutics
Omega Therapeutics
NA
NA
NA
-1.11
-1.29
-0.25
NA
0.48
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Omega Therapeutics
Omega Therapeutics
Buy
$67.3M
-92.37%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Omega Therapeutics

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.36M → 2.13M (in $), with an average decrease of 9.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -29.68M → -16.30M (in $), with an average increase of 16.8% per quarter

  • Vs VRTX

    In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 99.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 144.6% return, outperforming this stock by 238.6%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    52.99%

  • FMR Inc

    11.32%

  • Harbourvest Partners, LLC

    6.37%

  • State Of Wisconsin Investment Board

    3.37%

  • Artal Group S A

    2.40%

  • Vanguard Group Inc

    2.02%

Company Information

omega therapeutics™ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. the company’s platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. we are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines

Organization
Omega Therapeutics
Employees
93
CEO
Mr. Mahesh Karande
Industry
Services

Discover More

FAQs